schizophrenia
Mental health · 2005–2026
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| risperidone Treatment of adult patients with schizophrenia. MRSC risperidone is indicated for the prevention of relapse of schizophrenia in adults following stabilisation… | Mar 2026 | Recommended with restriction | input received |
| aripiprazole Treatment of schizophrenia. The submission requested listing of a new pre-filled syringe dose form in 300 mg and 400 mg (once-monthly) strengths. | Jul 2025 | Recommended with restriction | none received |
| brexpiprazole Treatment of schizophrenia in adults; specifically, a new 0.5 mg tablet strength to facilitate dose titration in patients who require a less than 1 mg dose or… | Jul 2025 | Recommended | 2 individuals |
| paliperidone Maintenance treatment of schizophrenia in adults. | Jul 2025 | Recommended | none received |
| risperidone Treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone. | Mar 2024 | Recommended with restriction | none received |
| aripiprazole Maintenance treatment of schizophrenia in adults who are stabilised on aripiprazole once monthly injection (AOM). | Dec 2024 | Recommended with restriction | 2 individuals |
| paliperidone palmitate Maintenance treatment of schizophrenia in adult patients who have been adequately treated with 1-month paliperidone palmitate injectable product for at least… | Mar 2022 | Recommended with restriction | 2 individuals |
| cariprazine Treatment of schizophrenia in adult patients. | Nov 2020 | Recommended with restriction | none received |
| aripiprazole Acute and maintenance treatment of schizophrenia in adults; maintenance treatment to prevent recurrence of manic or mixed episodes of bipolar I disorder in… | Jul 2018 | Recommended with restriction | none received |
| clozapine Schizophrenia, as an alternative formulation to address supply shortage of the existing clozapine (Clopine Suspension®) on the PBS. | Jul 2018 | Recommended with restriction | no section in document |
| quetiapine Maintenance therapy for treatment of acute mania, bipolar I disorder, and schizophrenia. The submission requested change in listing to allow up to 5 repeats… | Mar 2018 | Recommended | no section in document |
| brexpiprazole Treatment of schizophrenia in adults. | Mar 2017 | Recommended with restriction | input received |
| paliperidone palmitate Treatment of patients with schizophrenia who have been adequately treated with paliperidone one month LAI for at least four months. | Nov 2016 | Recommended with restriction | input received |
| lurasidone Treatment of schizophrenia in adults. Proposed for use in patients not controlled satisfactorily or intolerant to atypical antipsychotic agents such as… | Mar 2015 | Not recommended | none received |
| aripiprazole Maintenance treatment of schizophrenia in patients on stable dose of aripiprazole long-acting injection. | Jul 2014 | Recommended with restriction | 2 individuals |
| lurasidone hydrochloride Treatment of schizophrenia in adults. | Mar 2014 | Not recommended | unclear |
| quetiapine Dose titration in schizophrenia, acute mania associated with bipolar 1 disorder, and maintenance treatment of bipolar 1 disorder. | Aug 2013 | Recommended with restriction | no section in document |
| asenapine Treatment of schizophrenia in adults. | Jul 2011 | Recommended with restriction | unclear |
| sertindole Treatment of schizophrenia in patients who have had prior treatment with at least one other antipsychotic. | Mar 2011 | Not recommended | unclear |
| paliperidone palmitate Acute and maintenance treatment of schizophrenia in adults. | Nov 2010 | Recommended with restriction | unclear |
| olanzapine pamoate monohydrate Maintenance treatment of schizophrenia in adults stabilised during acute treatment with oral olanzapine. | Jul 2009 | Recommended with restriction | no section in document |
| paliperidone Treatment of schizophrenia, including acute treatment and recurrence prevention. | Nov 2007 | Recommended with restriction | no section in document |
| paliperidone Treatment of schizophrenia, including acute treatment and recurrence prevention. | Nov 2007 | Recommended with restriction | no section in document |
| ziprasidone hydrochloride Treatment of schizophrenia. | Nov 2006 | Recommended with restriction | no section in document |
| ziprasidone hydrochloride Treatment of schizophrenia, including prevention of relapse and maintenance of clinical improvement during continuation therapy. | Nov 2006 | Recommended with restriction | no section in document |
| risperidone Treatment of schizophrenia in patients whose illness requires supervision and treatment at hospital outpatient clinics or affiliated mental health centres. | Jul 2005 | Recommended | no section in document |
What the PBS pays
$238M in government benefit over 2024–25, across 2,973,891 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| paliperidone | $73.8M |
| aripiprazole | $72.4M |
| clozapine | $26.1M |
| risperidone | $21.3M |
| quetiapine | $19.3M |
| brexpiprazole | $8.7M |
| lurasidone | $4.5M |
| lurasidone hydrochloride | $4.5M |
| asenapine | $3.7M |
| ziprasidone hydrochloride | $2.3M |
| cariprazine | $1.7M |
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 1 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| aripiprazoleAripiprazole for the treatment of schizophrenia in people aged 15 to 17 years | TA213 | recommended | 2011-01 |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| olanzapineAPO-OLANZAPINE ODT olanzapine 10 mg orally disintegrating tablet blist | 1997 | 149 |
| amisulprideAMISULPRIDE SANDOZ PHARMA amisulpride 100 mg uncoated tablet blister p | 2002 | 22 |
| haloperidolHALDOL DECANOATE haloperidol 150 mg/3 mL (as decanoate) Injection ampo | 1991 | 12 |
| droperidolDROLEPTAN droperidol 2.5mg/1mL injection | 1993 | 10 |
| chlorpromazineLARGACTIL SYRUP chlorpromazine hydrochloride 5mg/ml oral liquid | 1991 | 4 |
| flupentixol decanoateFLUANXOL CONCENTRATED DEPOT flupentixol decanoate 100mg/1mL injection | 1994 | 3 |
| zuclopenthixolCLOPIXOL ACUPHASE zuclopenthixol acetate 100 mg/2 mL injection ampoule | 1993 | 3 |
| zuclopenthixol decanoateCLOPIXOL DEPOT zuclopenthixol decanoate 200 mg/1 mL injection ampoule | 1993 | 1 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 7 of 16 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.